Japan $44 Billion Takeda Pharmaceutical Forms Cancer Treatment Partnership with Hong Kong-Listed $18 Billion China Pharmaceutical Company Innovent Biologics via $100 Million Equity Investment in Innovent Biologics & $11.4 Billion Payment for Medicine Rights of Innovent Biologics ($1.2 Billion Upfront Payment, $10.2 Billion Milestones)
26th October | Hong Kong
Japan Takeda Pharmaceutical ($44 billion market value) has announced to form a cancer treatment partnership with Hong Kong-listed China pharmaceutical company Innovent Biologics ($18 billion market value) via $100 million equity investment in Innovent Biologics & $11.4 billion payment for medicine rights of Innovent Biologics ($1.2 billion upfront payment, $10.2 billion milestones). Innovent Biologics – Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically. Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of the clinical and commercial facilities are in compliance with the cGMP standards of NMPA, FDA and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic cooperation with Eli Lilly, Adimab, Incyte, Hanmi and other international pharmaceutical companies. Takeda – Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
“ Japan $44 Billion Takeda Pharmaceutical Forms Cancer Treatment Partnership with Hong Kong-Listed $18 Billion China Pharmaceutical Company Innovent Biologics via $100 Million Equity Investment in Innovent Biologics & $11.4 Billion Payment for Medicine Rights of Innovent Biologics ($1.2 Billion Upfront Payment, $10.2 Billion Milestones) “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
Japan $44 Billion Takeda Pharmaceutical Forms Cancer Treatment Partnership with Hong Kong-Listed $18 Billion China Pharmaceutical Company Innovent Biologics via $100 Million Equity Investment in Innovent Biologics & $11.4 Billion Payment for Medicine Rights of Innovent Biologics ($1.2 Billion Upfront Payment, $10.2 Billion Milestones)
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
